Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

Sponsor
Vista Klinik
Study ID
NCT03393767
Phase
PHASE4
Status
Completed

Conditions

  • Age Related Macular Degeneration
  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at baseline as assessed by weekly high resolution optical coherence tomography (OCT). Detection of persisting or new signs of CNV activity at OCT triggers further ranibizumab treatments considering that any ranibizumab injections can maximally be applied as often as 2-weekly.

Key Dates

First listed
Jan 8, 2018
Start date
Dec 31, 2010
Status verified
Jan 2018
Primary completion
Oct 31, 2016
Completion
Dec 31, 2016

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: prospective 1- Arm
    OCT-guided high frequency intravitreal ranibizumab 0.5mg

Primary Outcome Measure

Change in CNV activity (any fluid) as assessed by High Resolution OCT [ Time Frame: 12 month OCT Assessment ]

Related Studies